What is Idiopathic Pulmonary Fibrosis (IPF)?
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults (typically in their 60s-70s), is limited to the lungs, and is defined by the radiologic and/or histopathologic pattern of usual interstitial pneumonia (UIP). 1, 2
Key Clinical Features
IPF presents with:
- Insidious onset of progressive exertional dyspnea (the hallmark symptom)
- Chronic dry cough
- Bibasilar inspiratory crackles on lung examination (fine, "Velcro-like")
- Digital clubbing in some patients
- Absence of constitutional symptoms or features suggesting systemic disease 2
The disease is invariably progressive and carries a poor prognosis, with median survival of 3-5 years from diagnosis. 3
Epidemiology and Risk Factors
- Predominantly affects men more than women
- Peak incidence in the sixth and seventh decades of life
- Rare in patients under 50 years old 2
Major risk factors include:
- Prior cigarette smoking (majority of patients)
- Gastroesophageal reflux disease
- Family history of interstitial lung disease (at least 30% have genetic predisposing factors)
- Chronic viral infections (Epstein-Barr virus, hepatitis C)
- Environmental/occupational exposures 2, 4
Pathophysiology
IPF represents abnormal wound healing and fibroproliferation in the lung parenchyma, leading to:
- Progressive scarring and architectural distortion
- Irreversible loss of lung function
- Eventual respiratory failure 1
The disease course is highly variable and unpredictable on an individual basis—periods of relative stability can be followed by rapid decline or acute exacerbations. 5, 6
Diagnosis
The diagnosis requires:
Exclusion of other known causes of interstitial lung disease (hypersensitivity pneumonitis, connective tissue disease, drug-induced lung disease, occupational exposures)
Presence of a UIP pattern on either:
Multidisciplinary discussion involving pulmonologists, radiologists, and pathologists is recommended for diagnostic decision-making. 2
Disease Progression
IPF progression manifests as:
- Decline in forced vital capacity (FVC)
- Worsening dyspnea and exercise capacity
- Deterioration in quality of life
- On HRCT: increased extent of UIP pattern, increased honeycombing, progression of traction bronchiectasis 1, 5
Critical pitfall: A period of stable FVC does not predict future stability—the disease remains relentlessly progressive, requiring frequent monitoring every 3-6 months. 1, 5
Management Approach
Treatment includes both pharmacological and non-pharmacological interventions:
Pharmacological
- Antifibrotic therapy with nintedanib or pirfenidone (both FDA-approved, slow disease progression but are not curative) 1, 7
Non-pharmacological
- Oxygen supplementation for hypoxemia
- Pulmonary rehabilitation
- Symptom management (cough, dyspnea, anxiety) with palliative care involvement 1
Comorbidity Management
Evaluate and treat:
- Pulmonary hypertension
- Gastroesophageal reflux
- Obstructive sleep apnea
- Lung cancer screening 1
Lung Transplantation
Patients at increased risk of mortality should be referred for lung transplant evaluation at diagnosis—this is the only treatment that can substantially increase both duration and quality of life. 1, 3
Acute Exacerbations
Acute exacerbations represent unpredictable episodes of severe respiratory deterioration characterized by:
- Worsening dyspnea over days to weeks
- New ground-glass opacification on HRCT
- No alternative explanation (infection, heart failure, pulmonary embolism)
These may be treated with corticosteroids, though mechanical ventilation is not recommended for the majority of patients with respiratory failure. 1